Loading
A phase 1/2 trial of 177Lu-NYM032 injection in prostate cancer, run by Norroy Bioscience Co., LTD, active and no longer recruiting.
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC is a phase 1/2 interventional study registered as NCT06383052 by Norroy Bioscience Co., LTD, with 30 participants enrolled, started 2024-04-26 and due to reach its primary completion in 2025-06-30. Interventions recorded: 177Lu-NYM032 injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PSMA, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Norroy Bioscience, Prostate cancer and the tag pipeline.
Shares Norroy Bioscience, Prostate cancer and the tag pipeline.
Shares PSMA, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/